ARTICLE | Company News
Ovid Therapeutics, Stemina deal
February 17, 2017 8:16 PM UTC
Ovid and Stemina's NeuroPointDX diagnostics division partnered to identify biomarkers associated with Angelman Syndrome to assess patient responses to Ovid's gaboxadol (OV101). The collaboration will ...
BCIQ Target Profiles